+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

G-Protein Coupled Receptors (GPCRs) - Global Market Trajectory & Analytics

  • ID: 1227782
  • Report
  • May 2021
  • Region: Global
  • 359 Pages
  • Global Industry Analysts, Inc

FEATURED COMPANIES

  • Abcam plc
  • HD Biosciences Co., Ltd
  • Merck KGaA
  • Perkin Elmer Inc
  • Promega Corporation
  • QIAGEN N.V.
Global G-Protein Coupled Receptors (GPCRs) Market to Reach $3.7 Billion by 2026
G-protein-coupled receptors (GPCRs) represent signal-transducing molecules that transmit signals to cells. They play a key role in converting extracellular stimulus into intracellular responses, and are therefore responsible for all physiological processes. Growth in the global market is set to be fueled by increased adoption of the receptors in drug discovery. There are right now quite a few drug candidates under preclinical and clinical studies and also a good number of approved drugs, which are driving the need for GPCR assays and screening for drug development. There is also a strongly growing demand for related assays due to growing number of biological drugs, biased agonists and allosteric modulators which target these receptors. Market growth is also anticipated to be driven by increased use of GPCRs for decoding metastasis and growth of tumors and developing effective lines of treatment. Increasing prevalence of cardiovascular and respiratory diseases and such other lifestyle-induced issues also promotes market growth. Additionally, research studies targeting orphan GPCRs are seen as a lucrative area of focus.

Amid the COVID-19 crisis, the global market for G-Protein Coupled Receptors (GPCRs) estimated at US$2.6 Billion in the year 2020, is projected to reach a revised size of US$3.7 Billion by 2026, growing at a CAGR of 5.7% over the analysis period. Cell Lines, one of the segments analyzed in the report, is projected to record a 5.6% CAGR and reach US$1.5 Billion by the end of the analysis period. After a thorough analysis of the business implications of the pandemic and its induced economic crisis, growth in the Detection Kits segment is readjusted to a revised 6.3% CAGR for the next 7-year period.

The U.S. Market is Estimated at $1 Billion in 2021, While China is Forecast to Reach $296.6 Million by 2026
The G-Protein Coupled Receptors (GPCRs) market in the U.S. is estimated at US$1 Billion in the year 2021. China, the world`s second largest economy, is forecast to reach a projected market size of US$296.6 Million by the year 2026 trailing a CAGR of 8.4% over the analysis period. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 4.9% and 5.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.4% CAGR. North America is the largest GPCR market currently, owing to factors such as significant investments in cancer studies, increased emphasis on drug discovery and speedy approval of GPCR targeted drugs in the region. Growth in the Asia-Pacific region is set to be propelled by burgeoning population, rising incident of cancer, and increasing focus on contract research activities.

Cell Culture Reagents Segment to Reach $6 01.6 Million by 2026
In the global Cell Culture Reagents segment, USA, Canada, Japan, China and Europe will drive the 4.9% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$370.6 Million in the year 2020 will reach a projected size of US$518.5 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$55.9 Million by the year 2026.

Select Competitors (Total 52 Featured) - - Abcam plc- Addex Pharmaceuticals Ltd.- Arena Pharmaceuticals Inc.- Becton-Dickinson and Company- Eurofins DiscoverX Corporation- HD Biosciences Co., Ltd- Merck KGaA- Perkin Elmer Inc- Promega Corporation- QIAGEN N.V.- Thermo Fisher Scientific, Inc.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Abcam plc
  • HD Biosciences Co., Ltd
  • Merck KGaA
  • Perkin Elmer Inc
  • Promega Corporation
  • QIAGEN N.V.
I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Impact of Covid-19 and a Looming Global Recession
  • GPCR: An Introduction
  • Important Role of GPCRs in Drug Discovery
  • Popular Types of GPCRs of Therapeutic Interest
  • Classification of GPCRs
  • Orphan GPCRs: A Promising Area for Drug Discovery
  • GPCR Signaling Pathways
  • Physiological Roles Performed by GPCRs
  • Outlook
  • Geographic Market Analysis
  • Challenges
  • Competition
  • Recent Market Activity
  • World Brands
2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS
  • Therapeutic Potential of GPCRs Gains Wide Recognition
  • Allosteric Modulators and Implication of Allostery in Drug Discovery
  • GPCRs Registered as Targets for Approved Drugs with EMBL-CHEMBL, IUPHAR, and The DrugBank
  • Exhibit 1: GPCRs Registered as Targets for Approved Drugs with EMBL-CHEMBL
  • Exhibit 2: GPCRs Registered as Targets for Approved Drugs with International Union of Basic and Clinical Pharmacology (IUPHAR)
  • Exhibit 3: GPCRs Registered as Targets for Approved Drugs with The DrugBank
  • Exhibit 4: FDA Approved GPCR Targeting Drugs (Excl. Diagnostic Agents) for the Period 2015-2019
  • Hurdles Faced…
  • Developments in Structural Biology and Receptor Pharmacology Offer Novel Opportunities to GPCR Drug Discovery
  • In Silico Approaches Underway for GPCR Drug Screening
  • Microfluidic Cell Technology Holds Potential
  • Pipeline GPCR Drug Candidates Widen Prospects
  • Exhibit 5: Select GPCR Small Molecule Drugs in Active Clinical Development
  • Exhibit 6: GPCR Ligands (Agonist) in Phase III Clinical Development
  • Exhibit 7: GPCR Ligands (Antagonist) in Phase III Clinical Development
  • New Indications to Aid Growth
  • CRISPR Holds Potential to Speed Up GPCR-based Drug Discovery
  • GPCR-targeted Drugs and Role in Cancer Treatment
  • Exhibit 8: Select FDA Approved Drugs and Antibodies against Various Cancer Types
  • Exhibit 9: Potential GPCR targets for Cancer Treatment
  • Exhibit 10: Anti GPCRs Drugs and Antibodies under Clinical Trials
  • Rising Incidence of Cancer to Drive Drives Opportunities
  • Exhibit 11: Global Cancer Incidence: Number of New Cancer Cases in Million for the Years 2018, 2020, 2025, 2030, 2035 and 2040
  • Exhibit 2: Global Number of New Cancer Cases and Cancer-related Deaths by Cancer Site for 2018
  • GPCRs Evolve as Important targets for developing novel therapeutics for Neurodegerative Disorders
  • Exhibit 12: Number of Individuals Suffering from Alzheimer's in the US: 2020 and 2025
  • Exhibit 13: Global Aging Population Statistics for the 65+ Age Group in Million by Geographic Region for the Years 2019, 2025, 2035 and 2050
  • GPCRs: An Important Target for Cardiovascular Drugs
  • Exhibit 14: Fatalities by Heart Conditions - Estimated Percentage Breakdown for Cardiovascular Disease, Ischemic Heart Disease, Stroke, and Others
  • GPCR Screening and Targeting Technologies
4. GLOBAL MARKET PERSPECTIVE

III. MARKET ANALYSIS

UNITED STATES

CANADA

JAPAN

CHINA

EUROPE

FRANCE

GERMANY

ITALY

UNITED KINGDOM

REST OF EUROPE

ASIA-PACIFIC

REST OF WORLD

IV. COMPETITION
  • Total Companies Profiled: 52
Note: Product cover images may vary from those shown
  • Abcam plc
  • Addex Pharmaceuticals Ltd.
  • Arena Pharmaceuticals Inc.
  • Becton-Dickinson and Company
  • Eurofins DiscoverX Corporation
  • HD Biosciences Co., Ltd
  • Merck KGaA
  • Perkin Elmer Inc
  • Promega Corporation
  • QIAGEN N.V.
  • Thermo Fisher Scientific, Inc.
Note: Product cover images may vary from those shown
Adroll
adroll